RT Journal Article
T1 Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study
A1 Epaillard, Nicolas
A1 Parent, Pauline
A1 Loriot, Yohann
A1 Lavaud, Pernelle
A1 Vera-Cea, E-B.
A1 Martinez-Chanza, Nieves
A1 Rodriguez-Vida, Alejo
A1 Dumont, Clement
A1 Lozano, Rebeca
A1 Llácer, Casilda
A1 Ratta, Raffaele
A1 Oudard, Stephane
A1 Thibault, Constance
A1 Auclin, Edouard
K1 Urinary bladder neoplasms
K1 Variant histology
K1 Drug therapy
K1 Immunotherapy
K1 Mortality
K1 Neoplasias de la vejiga urinaria
K1 Quimioterapia
K1 Inmunoterapia
K1 Mortalidad
AB Introduction: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers.Materials: Multicenter retrospective analysis of patients treated for advanced or metastatic VH or non-UC bladder cancers. Primary endpoint was overall response rate (ORR) according to treatment line, regimen and histology subtype. Secondary endpoints were progression-free survival (PFS) and overall survival (OS).Results: Between 2005 and 2020, 46 patients from seven centers were included. The median age was 66 years (58.75; 74.75), 65.2% were male and 67.2% presented VH. At first line, the ORR for the entire population was 54.4% and median OS was 21.6 months (95% confidence interval [CI]: 14.2-38.6). The ORR of the 37 patients treated with chemotherapy at first line was 62.2% with median PFS and OS of 7.3 (95% CI: 4.5-8.6) and 21.6 months (95% CI: 14.2-35.7), respectively. Dose dense MVAC and platinum doublet chemotherapy had the highest ORR (71.4% and 65.2%). The 9 patients treated with immunotherapy at first line had an ORR of 22.2%, a median PFS of 3.3 months (95% CI:2.3-NR) and the median OS was not reached (95% CI:13.8-NR). Response to treatment varied depending on the histological sub-types and on the treatment type.Conclusion: Chemotherapy and immunotherapy have shown to be effective in VH or non-UC cancers, a rare histological subtype for which we currently have very little data in the literature.
PB Frontiers
YR 2021
FD 2021-05-20
LK http://hdl.handle.net/10668/3894
UL http://hdl.handle.net/10668/3894
LA en
NO Epaillard N, Parent P, Loriot Y, Lavaud P, Vera-Cea EB, Martinez-Chanza N, et al. Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study. Front Oncol. 2021 May 20;11:671969
DS RISalud
RD Apr 8, 2025